Home
|
Stock Information
|
Contact Us
Technology
Unique Platform
Treatment & Cure
What is RNAi?
Synthetic vs Expressed RNAi
Bibliography
Glossary
|
Intellectual Property
ddRNAi
Patent Estate
IP Actions
|
Pipeline & Partners
Pipeline Summary
In-house Programs
Out-licensed Programs
Licensing
Partners
|
Corporate
Overview
Management
Board
Investigators
Policies
|
Investors
Investor Information
2012 AGM
Annual Reports
Governance
ASX Stock Info
|
News
Media Releases
ASX Releases
Archived Releases
Events
|
Resources
Sitemap
Website sitemap
Home
Technology
Unique Platform
Treatment & Cure
What is RNAi?
siRNA vs shRNA
Bibliography
Glossary
Intellectual Property
ddRNAi Patent
Patent Estate
IP Actions
Pipeline & Partners
In-House Pipeline
Out-licensed Programs
Programs
Licensing
Partnes
Corporate
Overview
Management
Board
Investigators
Policies
Investors
Investor Info
2011 AGM
Annual Reports
ASX Stock Info
Governance
News
Media Releases
ASX Releases
Archived
Events
Contact
“Present shRNA expression systems provide good target knockdown and have not generally resulted in unexpected toxicities.”
Snove & Rossi
Nature Methods 2006
Read the paper
